Journal of Clinical Investigation · 2010 · 252 citations · 70 references
MedicineImmunologyOncologyCancer ImmunologyGene TherapyImmunotherapyAntitumor T Cell ResponsesCancer ImmunotherapyChimeric Antigen Receptor T-cell TherapyImmunotherapy For Solid TumorsT Cell Responses To TumorsTargeted Cancer TherapyAntitumor Immune ActivationAutologous Car T-cell TherapyGene-targeted TherapyMetastatic Melanoma TreatmentSyngeneic Tumor ModelsT Cell-based ImmunotherapyTumor Vasculature TargetingVegf Pathway Inhibition
Immunotherapies based on adoptive cell transfer are highly effective in the treatment of metastatic melanoma, but the use of this approach in other cancer histologies has been hampered by the identification of appropriate target molecules. Immunologic approaches targeting tumor vasculature provide a means for the therapy of multiple solid tumor types. We developed a method to target tumor vasculature, using genetically redirected syngeneic or autologous T cells. Mouse and human T cells were engineered to express a chimeric antigen receptor (CAR) targeted against VEGFR-2, which is overexpressed in tumor vasculature and is responsible for VEGF-mediated tumor progression and metastasis. Mouse and human T cells expressing the relevant VEGFR-2 CARs mediated specific immune responses against VEGFR-2 protein as well as VEGFR-2-expressing cells in vitro. A single dose of VEGFR-2 CAR-engineered mouse T cells plus exogenous IL-2 significantly inhibited the growth of 5 different types of established, vascularized syngeneic tumors in 2 different strains of mice and prolonged the survival of mice. T cells transduced with VEGFR-2 CAR showed durable and increased tumor infiltration, correlating with their antitumor effect. This approach provides a potential method for the gene therapy of a variety of human cancers.
70
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley, John R. Wunderlich, Paul F. Robbins et al. · Science · 2002 · 2.8K citations · Full text
Life Sciences, Immunology, Oncology +17
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
Richard A. Morgan, Mark E. Dudley, John R. Wunderlich et al. · Science · 2006 · 2.6K citations · Full text
Medicine, Immunology, Oncology +14
Induction of angiogenesis during the transition from hyperplasia to neoplasia
J Folkman, Karol Watson, Donald E. Ingber et al. · Nature · 1989 · 1.9K citations
Medicine, Cell Biology, Oncology +10